VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Gilead Sciences, Inc. vs Texas Roadhouse, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisTexas Roadhouse, Inc.
TXRH · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Texas Roadhouse, Inc.'s moat claims, evidence, and risks.
View TXRH analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 66 / 100 for Texas Roadhouse, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Texas Roadhouse, Inc. has 3 segments (93.8% in Texas Roadhouse).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Texas Roadhouse, Inc. has 4 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Texas Roadhouse, Inc.
Texas Roadhouse
Casual dining steakhouse restaurants
United States (plus international via franchise)
Consumers
Restaurant operator & franchisor
93.8%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Texas Roadhouse, Inc. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Texas Roadhouse, Inc. segments
Full profile >Texas Roadhouse
Competitive
Bubba's 33
Competitive
Other (Jaggers + retail initiatives)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.